Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study

PURPOSE: No established treatments exist for relapsed/refractory systemic light-chain (AL) amyloidosis. Bendamustine has shown potential in the treatment of multiple myeloma. We conducted a phase II, multicenter trial to assess the efficacy and safety of bendamustine with dexamethasone (ben-dex) in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Lentzsch, Suzanne, Lagos, Galina G., Comenzo, Raymond L., Zonder, Jeffrey A., Osman, Keren, Pan, Samuel, Bhutani, Divaya, Pregja, Silva, Sanchorawala, Vaishali, Landau, Heather
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2020
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7193746/
https://ncbi.nlm.nih.gov/pubmed/32083996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01721
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars